Cartalax
Cartalax is a very short synthetic peptide marketed as a cartilage-specific bioregulator, from the same Russian research tradition that produced Epithalon and Pinealon. It's important to know upfront that independently verifiable, peer-reviewed primary research specifically on Cartalax is very limited, most of what circulates about it traces back to vendor marketing material rather than published studies.
- Sequence
- 3 to 4 amino acids (vendor sources vary on exact sequence)
- Half-Life
- Not well established; published data is limited
- Format
- Lyophilized powder
What Is Cartalax?
Cartalax is described as a short peptide developed within the Khavinson bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, the same tradition that produced Epithalon, Pinealon, and Thymalin. Each peptide in this program is proposed to target a specific tissue type, and Cartalax is marketed specifically toward cartilage and connective tissue.
It's important to be direct here: unlike Epithalon and Thymalin, which have identifiable published studies attached to specific author names and journals, a search for Cartalax-specific peer-reviewed research did not surface verifiable primary studies. Vendor and marketing sources describe cartilage-related activity and cite general Khavinson group publications on tissue-specific gene regulation, but these citations are vague or unconfirmed rather than pointing to a dedicated, checkable study on Cartalax itself.
What Cartalax is Being Researched For?
Cartilage and Joint Tissue (as Marketed)
Vendor and secondary sources describe Cartalax as supporting chondrocyte gene expression and cartilage cell proliferation, consistent with the general Khavinson bioregulator framework applied to cartilage tissue specifically.
The Broader Khavinson Bioregulator Framework
The general concept behind this peptide, that very short peptides can influence tissue-specific gene expression, does have supporting research for other compounds in the same program, such as Epithalon's telomerase research. Whether that framework has been independently confirmed for Cartalax specifically is a separate, unresolved question.
How Cartalax Is Described as Working
A Proposed Gene-Expression Mechanism
Vendor sources describe Cartalax as working similarly to other Khavinson bioregulators, by influencing gene expression in target cells, in this case chondrocytes, rather than acting through a surface receptor. This mirrors the proposed mechanism described for Pinealon and Epithalon, but as with the research base itself, this claim for Cartalax specifically has not been traced to a verifiable, independently checkable primary study.
Reconstitution and Handling
Cartalax is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.
Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Keel Bio's calculator is a commonly used tool for this. Once reconstituted, the solution is kept refrigerated to help preserve its stability.
Key Takeaways
Cartalax is marketed as a cartilage-specific member of the Khavinson bioregulator family, but its own independent, peer-reviewed research base could not be verified through standard literature search, in contrast to some other peptides from the same program. Anyone researching Cartalax should treat vendor claims about its mechanism and effects as unverified until a specific, citable primary source can be identified, rather than assuming it carries the same evidence weight as its better-documented sibling peptides.
Frequently Asked Questions
What is Cartalax made of?
It's described as a very short synthetic peptide from the Khavinson bioregulator program, though vendor sources are inconsistent about its exact amino acid sequence.
What has Cartalax been studied for?
It's marketed for cartilage and joint tissue research, but independently verifiable, peer-reviewed studies specifically on Cartalax are very limited.
Is Cartalax the same as other Khavinson peptides?
It shares a general design philosophy with peptides like Epithalon and Pinealon, but each is marketed as targeting a different tissue. Cartalax's own dedicated evidence base is considerably thinner than some others in the same family.
Has Cartalax been tested in humans?
No verifiable human clinical trial data was identified.
Should Cartalax's research base be trusted the same way as Epithalon's?
No. Epithalon has identifiable, citable published studies, even with the caveat that they come from one research group. Cartalax's claims are largely sourced from vendor marketing material rather than checkable primary literature.
Related Reading
For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.